Trial Profile
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Etrumadenant (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Zimberelimab (Primary)
- Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms ARC-3
- Sponsors Arcus Biosciences
- 25 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 May 2021 According to an Arcus Biosciences media release, data from this study are expected in the first half of 2022.
- 10 Apr 2021 Updated results for safety in all patients and efficacy in 3L plus patients presented at the 112th Annual Meeting of the American Association for Cancer Research